目的 Chimeric antigen receptor-modified(CAR)T-cell immunotherapy is a novel promising therapy for treatment of B-cell malignancy.Cytokine release syndrome(CRS)and infection are the most common adverse events during CAR T-cell therapy.Similar clinical presentation of concurrent CRS and infection makes it difficult to differentially diagnose and timely treat.